A double trial success from Roche sees it eyeing a combination therapy in lucrative first-line lung cancer, and wider use of its just-approved haemophilia drug, Hemlibra.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
